// App-Quantinova.ai

PB1723 : ADORE: A RANDOMIZED, OPEN-LABEL, PHASE 1/2 OPEN-PLATFORM STUDY EVALUATING SAFETY AND EFFICACY OF NOVEL RUXOLITINIB COMBINATIONS IN PATIENTS WITH MYELOFIBROSIS

Researchers

Presenter

  • David Ross

Principal Investigators

  • Florian Heidel

  • Andrew Perkins

  • Kate Burbury

  • Thomas Lehmann

  • Vikas Gupta

  • Claire Harrison

  • Jean-Jacques Kiladjian

  • Alessandro Vannucchi

  • Marielle Wondergem

  • Robert Pack

  • Monika Wroclawska

  • Celine Wilke

  • Angela Zhang

  • Andreas Reiter

Medical Centers

  • Universitaetsfrauenklinik Greifswald, Greifswald, Germany

  • Universitätsklinikum Mannheim,Mannheim,Germany

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Australian Centre For Blood Diseases, Monash University, Melbourne, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Royal Adelaide Hospital, Adelaide, Australia

  • VU University Medical Center, Amsterdam, Netherlands

  • Novartis Pharma Corp, Basel, Switzerland

  • Hôpital Saint-Louis &amp

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

  • Université de Paris,Paris,France

Locations

  • Germany

  • Australia

  • Switzerland

  • Canada

  • Netherlands

  • United Kingdom

  • Italy

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • SelG1

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04097821

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved